Onyx Pharma's (ONXX) Kyprolis Receives FDA Approval as Multiple Myeloma Treatment

The Multiple Myeloma Research Foundation (MMRF) today announced that its partner, Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), received U.S. Food and Drug Administration (FDA) approval for Kyprolis™ (carfilzomib) for the treatment of patients with multiple myeloma who have received at least two prior therapies, including Velcade (bortezomib) for Injection and an immunomodulatory agent, such as Thalomid (thalidomide) or Revlimid (lenalidomide), and have demonstrated disease progression on or within 60 days of completion of the last therapy. The approval of Kyprolis is based on response rate.

The MMRF’s affiliate organization, the Multiple Myeloma Research Consortium (MMRC), a clinical trials network of 16 leading multiple myeloma centers in North America, has bolstered the clinical development of Kyprolis for the past six years, providing clinical trial support and resources, including driving accrual to the pivotal Phase IIb trial (003-A1) that supported the accelerated approval of the treatment.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• Gray Media closes $750M note offering to refinance higher-rate debt
• Solowin Holdings marks 10 years, expands into stablecoins and AI